Q3 2025 Natera Inc Earnings Call Transcript
Key Points
- Natera Inc (NTRA) reported a 35% increase in revenue, reaching $592 million for Q3 2025, compared to the same quarter last year.
- The company processed 202,000 clinical MRD tests, marking a growth of over 21,500 units from the previous quarter.
- Gross margin improved significantly to 64.9%, up nearly 1.5 percentage points from the previous quarter.
- Natera Inc (NTRA) raised its 2025 revenue guidance by $160 million, now expecting revenues between $2.18 billion and $2.26 billion.
- The company announced the expansion of its Fetal Focus product to cover over 20 genes, following positive feedback from its initial launch.
- Natera Inc (NTRA) faces challenges with one-time expenses totaling around $60 million, impacting overall financial performance.
- The company anticipates a modest increase in R&D expenses to support MoldDX coverage, which could affect short-term profitability.
- Despite strong growth, the company acknowledges the potential for variability in quarterly performance, particularly in new patient starts.
- The company is cautious about the impact of biomarker state reimbursement, which may take time to fully materialize.
- Natera Inc (NTRA) faces competitive pressures in the women's health space, particularly from competitors with mother-only assays.
Welcome to Neterra's 20,253 quarter financial results conference call. At this time, all participants are in a list in only the mode. Following management's prepared remarks, we will hold a question-and-answer session. To ask a question at that time, please press star, followed by 1 on your touchstone phone. If anyone has difficulty hearing the conference, please press 0 for operator assistance. As a reminder, this conference call is being recorded today, November 6, 2025. I would now like to turn the conference call over to Michael Brophy, Chief Financial Officer.
Please go ahead.
Thanks, operator. Good afternoon.
Thank you for joining our conference call to discuss the results of our 3rd quarter of 2025.
On the line, I'm joined by Steve Chapman, our CEO Solomon Moskovitz, President of clinical diagnostics, and Alex Alein, general manager of oncology and our Chief Medical Officer.
Today's conference call is being broadcast live via webcast. We will be referring to a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
